While hormonal therapy targeting ER and PR is used in treatment of patients with endometrial cancers [15], there are limited studies evaluating the effects of hormone therapy targeting AR [14]; complicated by the contradictory findings regarding the androgen levels in females, as mentioned above. The gene discussed is ESR1; the disease is endometrial cancer.